Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30587822 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KIF11CYP2A6VCAM1ALDH1A3 | |
| SCHEMBL4166153 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KIF11CYP2A6VCAM1ALDH1A3 | |
| SCHEMBL29956305 | 0.79 | CYP2A6 (0.66) | ALDH1A1KIF11CYP2A6KDM4EMAPT | |
| SCHEMBL9377060 | 0.79 | CYP2A6 (0.66) | ALDH1A1KIF11CYP2A6KDM4EMAPT | |
| SCHEMBL29147512 | 0.78 | KIF11 (0.47) | ALDH1A1KIF11CYP2A6ALDH1A3KDM4E | |
| SCHEMBL21623870 | 0.78 | KDM4E (0.48) | ALDH1A1KIF11CYP2A6KDM4EMAPT | |
| SCHEMBL19586691 | 0.78 | CYP2A6 (0.50) | ALDH1A1KIF11CYP2A6ALDH1A3ALDH3A1 | |
| SCHEMBL28878089 | 0.74 | KIF11 (0.44) | ALDH1A1KIF11CYP2A6KDM4EMAPT | |
| SCHEMBL22158783 | 0.73 | IMPDH2 (0.54) | KIF11CYP2A6HSD17B10TTKIMPDH2 | |
| SCHEMBL9372571 | 0.71 | HTR2A (0.45) | KIF11CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650985-A | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109195972-B | Heterocyclic compounds as RET kinase inhibitors | 癌症研究科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-8680150-B2 | Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| CN-101679324-B | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2012-10-03 | — | — | CN | disclosed |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| EP-2168952-A1 | MORPHOLINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| CN-101679324-A | Morpholine derivatives | MITSUBISHI TANABE PHARMA CORP | 2010-03-24 | — | — | CN | disclosed |
| EP-1603572-A4 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1603572-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | ALDH1A1 2202/4885KIF11 1509/4885CYP2A6 630/4885 |
| US-20110003851-A1 | SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS | MPL, CSF3R, CSF1R | ALDH1A1 3164/4885KIF11 4185/4885CYP2A6 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.